JOP20220219A1 - مشتقات نافثيريديين وبيريدو [3، 4-c] بيريدازين كمُعدِّلات لمستقبلات GABAA ألفا 5 - Google Patents

مشتقات نافثيريديين وبيريدو [3، 4-c] بيريدازين كمُعدِّلات لمستقبلات GABAA ألفا 5

Info

Publication number
JOP20220219A1
JOP20220219A1 JOP/2022/0219A JOP20220219A JOP20220219A1 JO P20220219 A1 JOP20220219 A1 JO P20220219A1 JO P20220219 A JOP20220219 A JO P20220219A JO P20220219 A1 JOP20220219 A1 JO P20220219A1
Authority
JO
Jordan
Prior art keywords
gabaa
naphthyridine
pyrido
receptor modulators
pyridazine derivatives
Prior art date
Application number
JOP/2022/0219A
Other languages
English (en)
Inventor
Attila Potor
Olivér Dr Eli?S
Gy?Rgy Istv?N Dr T?R?S
G?Bor L?Szl? Dr Kapus
Gy?Rgy Szab?
Istv?N V?G?
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JOP20220219A1 publication Critical patent/JOP20220219A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركبات لها الصيغة (I) و/أو أملاح منها و/أو نواتج أيض نشطة بيولوجيًا منها و/أو عقاقير أولية منها و/أو ذوابات منها و/أو هيدرات منها و/أو صور متعددة منها لها ألفة وانتقائية خاصة بالوحدة الفرعية ألفا 5 من المستقبل A لحمض جاما- أمينو بيوتريك والتي تعمل في شكل مُعدِّلات فراغية موجبة لـ GABAA andalpha;5، وبالتالي فهي مفيدة في معالجة أو الوقاية من أمراض مرتبطة بمستقبل GABAA andalpha;5 ، وعملية خاصة بالتحضير والمركبات الوسيطة لتلك العملية والتركيبات الصيدلانية المشتملة عليها سواءً بمفردها أو في توليفة مع مكونات فعالة أخرى واستخدامها في شكل أدوية.
JOP/2022/0219A 2020-03-26 2021-03-25 مشتقات نافثيريديين وبيريدو [3، 4-c] بيريدازين كمُعدِّلات لمستقبلات GABAA ألفا 5 JOP20220219A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP2000113 2020-03-26
PCT/IB2021/052486 WO2021191838A1 (en) 2020-03-26 2021-03-25 NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (1)

Publication Number Publication Date
JOP20220219A1 true JOP20220219A1 (ar) 2023-01-30

Family

ID=89666363

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0219A JOP20220219A1 (ar) 2020-03-26 2021-03-25 مشتقات نافثيريديين وبيريدو [3، 4-c] بيريدازين كمُعدِّلات لمستقبلات GABAA ألفا 5

Country Status (20)

Country Link
US (1) US20240067637A1 (ar)
EP (1) EP4126859A1 (ar)
JP (1) JP2023520647A (ar)
KR (1) KR20220160061A (ar)
CN (1) CN115348962A (ar)
AR (1) AR121666A1 (ar)
AU (1) AU2021244926A1 (ar)
BR (1) BR112022019128A2 (ar)
CA (1) CA3171441A1 (ar)
CL (1) CL2022002568A1 (ar)
CO (1) CO2022014877A2 (ar)
CU (1) CU24714B1 (ar)
EC (1) ECSP22082367A (ar)
IL (1) IL296716A (ar)
JO (1) JOP20220219A1 (ar)
MX (1) MX2022011933A (ar)
PE (1) PE20221836A1 (ar)
TW (1) TW202202495A (ar)
WO (1) WO2021191838A1 (ar)
ZA (1) ZA202211414B (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2100338A1 (hu) * 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728900B1 (fr) * 1994-12-29 1997-01-31 Synthelabo Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
EP1937674A1 (en) * 2005-10-11 2008-07-02 F.Hoffmann-La Roche Ag Isoxazole derivatives
JP2009514924A (ja) * 2005-11-09 2009-04-09 エフ．ホフマン−ラ ロシュ アーゲー ３−アリール−イソオキサゾール−４−カルボニル−ベンゾフラン誘導体
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
RU2013144579A (ru) * 2011-03-04 2015-04-10 Лексикон Фармасьютикалз, Инк. Ингибиторы киназы mst1 и способы их применения
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9206160B2 (en) * 2012-06-26 2015-12-08 Saniona Aps Phenyl triazole derivative and its use for modulating the GABAA receptor complex
CN104411703A (zh) 2012-06-26 2015-03-11 萨尼奥纳有限责任公司 苯基三唑衍生物及其调节gabaa受体复合体的用途
CN102924452B (zh) * 2012-11-16 2015-01-21 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US9296747B1 (en) * 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
CN107922348A (zh) * 2015-06-22 2018-04-17 大日本住友制药株式会社 双环杂环酰胺衍生物
US10556907B2 (en) 2015-08-28 2020-02-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic compounds as S1P modulators
DK3439665T3 (da) 2016-03-18 2022-09-26 Uwm Res Foundation Inc Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister
LT3551627T (lt) * 2016-12-08 2022-04-25 F. Hoffmann-La Roche Ag Nauji izoksazolilo eterio dariniai kaip gaba a alfa5 teigiami alosteriniai moduliatoriai (pam)
EP3560494A4 (en) * 2016-12-20 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. MEDICINAL PRODUCT TARGETING A CARCINOUS STEM CELL
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
EP3807269A1 (en) 2018-06-13 2021-04-21 F. Hoffmann-La Roche AG New isoxazolyl ether derivatives as gaba a alpha5 pam
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
BR102019014802A2 (pt) * 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek

Also Published As

Publication number Publication date
CA3171441A1 (en) 2021-09-30
TW202202495A (zh) 2022-01-16
AR121666A1 (es) 2022-06-29
CU20220058A7 (es) 2023-05-11
CO2022014877A2 (es) 2022-10-31
MX2022011933A (es) 2022-10-20
CN115348962A (zh) 2022-11-15
ECSP22082367A (es) 2022-11-30
CU24714B1 (es) 2024-07-10
US20240067637A1 (en) 2024-02-29
JP2023520647A (ja) 2023-05-18
BR112022019128A2 (pt) 2022-11-08
KR20220160061A (ko) 2022-12-05
IL296716A (en) 2022-11-01
EP4126859A1 (en) 2023-02-08
AU2021244926A1 (en) 2022-11-03
WO2021191838A1 (en) 2021-09-30
PE20221836A1 (es) 2022-11-29
CL2022002568A1 (es) 2023-03-24
ZA202211414B (en) 2023-06-28

Similar Documents

Publication Publication Date Title
MX2021010674A (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos.
MX2021013941A (es) Inhibidores del inflamasoma nlrp3.
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
ES2668422T3 (es) Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
EP2021342A1 (en) PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM
MX2008015308A (es) 4-amino-pirido [3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10 y procedimientos para su preparacion.
US20090088423A1 (en) Methods and compositions for treating bacterial infections and diseases associated therewith
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
GEP20237581B (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
UA86617C2 (en) 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
GB0517175D0 (en) Compounds
WO2010084798A1 (ja) ３環性化合物
MX2024003076A (es) Compuestos espirociclicos.
JOP20220219A1 (ar) مشتقات نافثيريديين وبيريدو [3، 4-c] بيريدازين كمُعدِّلات لمستقبلات GABAA ألفا 5
MY196807A (en) Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
CA3011999A1 (en) Antimicrobial potentiators
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa
PH12020500548A1 (en) Triazolobenzazepines as vasopressin v1a receptor antagonists
MY195262A (en) Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-A]Pyrimidine Derivatives
US20110218195A1 (en) Methods and compositions for treating bacterial infections and diseases associated therewith
DE60235729D1 (de) 1,8-Naphthyridine als CRF Antagonisten
MX2023009285A (es) Compuestos novedosos.
MX2024003812A (es) Derivados de amina bicíclicos como moduladores de receptor gabaa a5.